処理中

しばらくお待ちください...

PATENTSCOPE は、メンテナンスのため次の日時に数時間サービスを休止します。サービス休止: 火曜日 25.01.2022 (12:00 午後 CET)
設定

設定

出願の表示

1. WO2020261619 - 医薬組成物

公開番号 WO/2020/261619
公開日 30.12.2020
国際出願番号 PCT/JP2020/000711
国際出願日 10.01.2020
IPC
A61K 45/00 2006.1
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
45A61K31/00~A61K41/00に属さない活性成分を含有する医薬品製剤
A61K 9/12 2006.1
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
9特別な物理的形態によって特徴づけられた医薬品の製剤
10分散剤;乳剤
12エアゾール;泡沫剤
A61K 9/14 2006.1
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
9特別な物理的形態によって特徴づけられた医薬品の製剤
14粒状剤,例.散剤
A61K 47/26 2006.1
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
47使用する不活性成分,例.担体または不活性添加剤,に特徴のある医薬品製剤;活性成分と化学結合した標的剤または修飾剤
06有機物質,例.天然または合成の炭化水素,ポリオレフィン,鉱油,ペトロラタムまたはオゾケライト
26炭水化物,例.糖アルコール,アミノ糖,核酸,単糖,二糖またはオリゴ糖;その誘導体,例.ポリソルベート,ソルビタン脂肪酸エステルまたはグリチルリチン
CPC
A23L 5/00
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A23B - A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT
5Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
A61K 31/192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
192having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
A61K 31/277
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
275Nitriles; Isonitriles
277having a ring, e.g. verapamil
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 31/517
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
出願人
  • 株式会社リコー RICOH COMPANY, LTD. [JP]/[JP] (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BN, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CL, CM, CN, CO, CR, CU, CY, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KM, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MG, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SY, SZ, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW)
  • 国立大学法人信州大学 SHINSHU UNIVERSITY [JP]/[JP] (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BN, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CL, CM, CN, CO, CR, CU, CY, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KM, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MG, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SY, SZ, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW)
  • 佐藤 隆 SATO, Takashi [JP]/[JP] (US)
  • 下里 剛士 SHIMOSATO, Takeshi [JP]/[JP] (US)
  • 森谷 樹 MORITANI, Tatsuru [JP]/[JP] (US)
  • 森永 匡彦 MORINAGA, Tadahiko [JP]/[JP] (US)
  • 佐藤 祐一 SATO, Yuichi [JP]/[JP] (US)
  • 小番 昭宏 KOTSUGAI, Akihiro [JP]/[JP] (US)
発明者
  • 佐藤 隆 SATO, Takashi
  • 下里 剛士 SHIMOSATO, Takeshi
  • 森谷 樹 MORITANI, Tatsuru
  • 森永 匡彦 MORINAGA, Tadahiko
  • 佐藤 祐一 SATO, Yuichi
  • 小番 昭宏 KOTSUGAI, Akihiro
代理人
  • 廣田 浩一 HIROTA, Koichi
優先権情報
2019-11828926.06.2019JP
公開言語 (言語コード) 日本語 (ja)
出願言語 (言語コード) 日本語 (JA)
指定国 (国コード)
発明の名称
(EN) PHARMACEUTICAL COMPOSITION
(FR) COMPOSITION PHARMACEUTIQUE
(JA) 医薬組成物
要約
(EN) A pharmaceutical composition that is characterized by including particles that include a water-soluble base material and a poorly water-soluble compound, wherein the water-soluble base material includes a rapidly water-soluble compound, and the poorly water-soluble compound is a kinase inhibitor and is present within the water-soluble base material in an amorphous condition.
(FR) L'invention concerne une composition pharmaceutique qui est caractérisée en ce qu'elle comprend des particules qui comprennent un matériau de base soluble dans l'eau et un composé peu soluble dans l'eau, le matériau de base soluble dans l'eau comprenant un composé rapidement soluble dans l'eau, et le composé peu soluble dans l'eau étant un inhibiteur de kinase et étant présent dans le matériau de base soluble dans l'eau dans un état amorphe.
(JA) 水溶性基材と、難水溶性化合物とを含有する粒子を含み、前記水溶性基材が、迅速水溶性化合物を含有し、前記難水溶性化合物がキナーゼ阻害剤であり、非晶質状態で前記水溶性基材内に存在することを特徴とする医薬組成物である。
Related patent documents
JP2021527336This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
国際事務局に記録されている最新の書誌情報